156 related articles for article (PubMed ID: 2141500)
1. TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors.
Toko T; Sugimoto Y; Matsuo K; Yamasaki R; Takeda S; Wierzba K; Asao T; Yamada Y
Eur J Cancer; 1990 Mar; 26(3):397-404. PubMed ID: 2141500
[TBL] [Abstract][Full Text] [Related]
2. A new triphenylethylene derivative, TAT-59; hormone receptors; insulin-like growth factor 1; and growth suppression of hormone-dependent MCF-7 tumors in athymic mice.
Iino Y; Takai Y; Ando T; Ohwada S; Yokoe T; Sugamata N; Takei H; Horiguchi J; Iijima K; Morishita Y
Cancer Chemother Pharmacol; 1994; 34(5):372-6. PubMed ID: 8070003
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of triphenylethylene derivative (TAT-59) against human breast carcinoma xenografts in nude mice.
Koh J; Kubota T; Asanuma F; Yamada Y; Kawamura E; Hosoda Y; Hashimoto M; Yamamoto O; Sakai S; Maeda K
J Surg Oncol; 1992 Dec; 51(4):254-8. PubMed ID: 1434657
[TBL] [Abstract][Full Text] [Related]
4. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
[TBL] [Abstract][Full Text] [Related]
5. Interaction of DP-TAT-59, an active metabolite of new triphenylethylene-derivative (TAT-59), with estrogen receptors.
Toko T; Matsuo K; Shibata J; Wierzba K; Nukatsuka M; Takeda S; Yamada Y; Asao T; Hirose T; Sato B
J Steroid Biochem Mol Biol; 1992 Nov; 43(6):507-14. PubMed ID: 1419885
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma.
Toko T; Shibata J; Sugimoto Y; Yamaya H; Yoshida M; Ogawa K; Matsushima E
Cancer Chemother Pharmacol; 1995; 37(1-2):7-13. PubMed ID: 7497599
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
Kawamura I; Mizota T; Kondo N; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1991 Oct; 57(2):215-24. PubMed ID: 1812300
[TBL] [Abstract][Full Text] [Related]
8. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249
[TBL] [Abstract][Full Text] [Related]
9. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer.
Toko T; Shibata J; Nukatsuka M; Yamada Y
Cancer Chemother Pharmacol; 1997; 39(5):390-8. PubMed ID: 9054952
[TBL] [Abstract][Full Text] [Related]
10. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
Chisamore MJ; Ahmed Y; Bentrem DJ; Jordan VC; Tonetti DA
Clin Cancer Res; 2001 Oct; 7(10):3156-65. PubMed ID: 11595710
[TBL] [Abstract][Full Text] [Related]
11. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen.
Löser R; Seibel K; Roos W; Eppenberger U
Eur J Cancer Clin Oncol; 1985 Aug; 21(8):985-90. PubMed ID: 4043181
[TBL] [Abstract][Full Text] [Related]
13. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
14. Differences in immunoreactivity of estrogen receptor (ER) in tamoxifen-sensitive and -resistant breast carcinomas: preclinical and first clinical investigations.
Naundorf H; Jost-Reuhl B; Becker M; Reuhl T; Neumann C; Fichtner I
Breast Cancer Res Treat; 2000 Mar; 60(1):81-92. PubMed ID: 10845812
[TBL] [Abstract][Full Text] [Related]
15. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
Gottardis MM; Jordan VC
Cancer Res; 1987 Aug; 47(15):4020-4. PubMed ID: 3607747
[TBL] [Abstract][Full Text] [Related]
16. The estrogenic and antiestrogenic activities of droloxifene in human breast cancers.
Kawamura I; Mizota T; Lacey E; Tanaka Y; Manda T; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1993 Sep; 63(1):27-34. PubMed ID: 8271528
[TBL] [Abstract][Full Text] [Related]
17. Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro.
Wei LL; Mangel WF; Katzenellenbogen BS
J Steroid Biochem; 1985 Dec; 23(6A):875-81. PubMed ID: 3937947
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.
Wolf DM; Langan-Fahey SM; Parker CJ; McCague R; Jordan VC
J Natl Cancer Inst; 1993 May; 85(10):806-12. PubMed ID: 8487325
[TBL] [Abstract][Full Text] [Related]
19. Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59).
Shibata J; Toko T; Saito H; Lykkesfeldt AE; Fujioka A; Sato K; Hashimoto A; Wierzba K; Yamada Y
Cancer Chemother Pharmacol; 2000; 45(2):133-41. PubMed ID: 10663628
[TBL] [Abstract][Full Text] [Related]
20. Regulation of estrogen receptor and epidermal growth factor receptor by tamoxifen under high and low estrogen environments in MCF-7 cells grown in athymic mice.
Koibuchi Y; Iino Y; Uchida T; Andoh T; Horii Y; Nagasawa M; Horiguchi J; Maemura M; Takei H; Yokoe T; Morishita Y
Oncol Rep; 2000; 7(1):135-40. PubMed ID: 10601607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
